000			03498cam a2200541Ki 4500
001			9780429295034
003			FlBoTFG
005			20220531132311.0
006			m o d
007			cr cnu|||unuuu
008			190701s2019 si ob 001 0 eng d
040			_aOCoLC-P _beng _erda _epn _cOCoLC-P
020			_a9780429295034 _q(electronic bk.)
020			_a0429295030 _q(electronic bk.)
020			_a9781000021110 _q(electronic bk. : Mobipocket)
020			_a1000021114 _q(electronic bk. : Mobipocket)
020			_a9781000021288 _q(electronic bk. : EPUB)
020			_a1000021289 _q(electronic bk. : EPUB)
020			_a9781000020946 _q(electronic bk. : PDF)
020			_a1000020940 _q(electronic bk. : PDF)
020			_z9789814800617
024	8		_a10.1201/9780429295034 _2doi
035			_a(OCoLC)1106526045
035			_a(OCoLC-P)1106526045
050		4	_aTP248.E5
072		7	_aMED _x009000 _2bisacsh
072		7	_aMED _x014000 _2bisacsh
072		7	_aMED _x071000 _2bisacsh
072		7	_aTDCW _2bicssc
082	0	4	_a660.6/34 _223
245	0	0	_aPharmaceutical Biocatalysis : _bFundamentals, Enzyme Inhibitors, and Enzymes in Health and Diseases / _cedited by Peter Grunwald.
264		1	_aSingapore : _bJenny Stanford Publishing, _c2019.
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
490	1		_aJenny Stanford series on biocatalysis ; _vvolume 4
520			_aThis book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-designer approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.
588			_aOCLC-licensed vendor bibliographic record.
650		0	_aEnzymes _xIndustrial applications.
650		0	_aPharmaceutical biotechnology.
650		7	_aMEDICAL / Biotechnology _2bisacsh
650		7	_aMEDICAL / Clinical Medicine _2bisacsh
650		7	_aMEDICAL / Pharmacology _2bisacsh
700	1		_aGrunwald, Peter.
856	4	0	_3Taylor & Francis _uhttps://www.taylorfrancis.com/books/9780429295034
856	4	2	_3OCLC metadata license agreement _uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
999			_c70472 _d70472